In 2023, the global Checkpoint Inhibitor Refractory Cancer Market is anticipated to be worth US$ 38.69 billion. With consumers becoming more concerned about the expanded indications of existing immunotherapies, the global market for Checkpoint Inhibitor Refractory Cancer is expected to grow at a CAGR of 11.26% between 2023 and 2033, totaling approximately US$ 112.43 billion by 2033.
Immunotherapy treatment methods are evolving and are one of the most important methods for cancer treatment. Checkpoint inhibitors, such as PD-1/PD-L1, use a focused approach to reduce toxicity, resulting in greater efficacy. The checkpoint inhibitors industry is growing due to the effectiveness of the medicines.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16133
Moreover, the high prevalence of cancer is the major factor that is responsible for the rise in the market revenue of checkpoint inhibitors. Also, the technological advancements and innovations will also accelerate the market growth over the analysis period.
Other factors including the rise in the cases of a different type of cancers where checkpoint inhibitors are in use, an increase in R&D activity, as well as expected commercial success of upcoming therapies which are going to resolve the issue of primary resistance, and a surge in the usage of approved checkpoint inhibitor therapies in the 7MM are all projected to fuel the revenue share of the market in the near future.
Moreover, the companies across the world are thoroughly working toward developing new drug therapy options, in order to treat a wide array of Checkpoint Inhibitor Refractory Cancers. Some of the key players, including BerGenBio, OncoSec Medical, Mirati Therapeutics, CatalYm, Checkmate Pharmaceuticals, among others, are involved in developing novel therapies for indications such as Melanoma, non-small cell lung cancer (NSCLC), advanced-stage, solid tumors, and others.
In addition, there has been an increase in demand for pembrolizumab (KEYTRUDA) worldwide, attributed to its proven efficiency to treat many FDA-Approved indications such as head and neck squamous cell cancer (HNSCC), non-small cell lung cancer (NSCLC), and melanoma. Hence, the market players are investing more for the development of these products, and this trend is anticipated to continue in the coming years, thus, fostering the market growth.
Further, the factors such as the growing burden of cancer on the global level has been increasing the use of checkpoint inhibitors, as these inhibitors are significant immune are used as front-line treatments for several types of cancer. Hence, with the increase in incidence of cancer, the use of checkpoint inhibitors is also increasing. This trend is expected to continue over the analysis period.
Key Takeaways:
- Global Checkpoint Inhibitor Refractory Cancer Market was valued at US$ 781.0Billion by 2022-end
- From 2018 to 2022, the market demand expanded at a CAGR of 5.5%
- By Application, the Non-Small Cell Lung segment of the market constitutes the bulk of the market with a market share of 37%
- By End-User, the Hospital Pharmacies segment dominates the market with a share of 48.3%
- From 2023 to 2033, Checkpoint Inhibitor Refractory Cancer sales are expected to flourish at a CAGR of 11.26%.
- By 2033, the market value of Checkpoint Inhibitor Refractory Cancer is expected to reach US$ 112.43 Billion.
A rapid increase in the global prevalence of several cancers globally is one of the major factors that is expected to escalate the growth of the checkpoint inhibitor refractory cancer market in the forthcoming years, remarks an FMI analyst.
Competitive Landscape
Prominent players in the Checkpoint Inhibitor Refractory Cancer market are Bristol-Myers Squibb, AstraZeneca, Merck, Genentech/Hoffmann-La Roche, Regeneron Pharmaceuticals, Merck KGaA, Pfizer, Bristol-Myers Squibb, Janssen Research and Development, LLC., 4D pharma plc., 4SC AG, OncoSec Medical, Mirati Therapeutics, Ascentage Pharma Group, and ENB Therapeutics, Inc., among others.
Recent Developments:
- In January 2020, Merck & Co. acquired ArQule Inc., a company that develops therapeutics based on its proprietary Activated Checkpoint Therapy platform.
- In July 2019, Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu for the prevention and treatment of influenza or flu in the United States.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-16133
Key Segments Covered in the Checkpoint Inhibitor Refractory Cancer Industry Analysis
Checkpoint Inhibitor Refractory Cancer Market by Type:
- PD-1 Inhibitors
- PD-L1 Inhibitors
Checkpoint Inhibitor Refractory Cancer Market by Application:
- Hodgkin Lymphoma
- Kidney Cancer
- Melanoma
- Non-Small Cell Lung Cancer
- Others
Checkpoint Inhibitor Refractory Cancer Market by End-User:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
